Human isotope fractional absorption studies comparing chelated Magnesium Glycinate vs. Citrate vs. 4% Oxide, CYP2R1/CYP27B1 magnesium-dependent Vitamin D3 activation trials, and Metformin-induced Vitamin B12 holotranscobalamin depletion. Explore 4,327 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Secukinumab provided sustained improvements in nail disease, signs and symptoms of PsA, and a low rate of radiographic progression through 2 years in patients with concomitant nail psoriasis.
Tildrakizumab week 28 nonresponders can be identified by week 16 PASI response.
In a retrospective analysis of hormone receptor-negative and lymph node-positive breast cancer patients randomized in an adjuvant phase III trial to 1-year low-dose metronomic methotrexate-based chemotherapy or no maintenance...
This unique ultrasound study shows that apart from improving the signs and symptoms of PsA, IL-17A inhibition with secukinumab leads to a rapid and significant reduction of synovitis in PsA patients.
We identified a total of 3,059 studies and finally included 15 studies in the meta-analysis.
Our analysis of the HERA trial suggests that RT does not significantly increase the risk of cardiotoxicity in HER-2-positive breast cancer patients treated with trastuzumab.
Even a < 5% weight loss can reduce breathing events, but a ≥ 5% and ideally ≥ 10% weight loss is necessary for reducing the prevalence of severe OSA.
Our head-to-head study demonstrated that liraglutide enhanced impaired brain activation and restored impaired cognitive domains in patients with type 2 diabetes, whereas dapagliflozin and acarbose did not.
Women living in South African informal settlements who witness or experience traumatic events were likely to experience IPV, and this increases when women were exposed to multiple types of events.
Primary vaccination with QIV was well tolerated and effective in protecting children aged 6-35 months against influenza.
In adult Chinese patients, dupilumab was effective in improving the signs and symptoms of AD and demonstrated a favourable safety profile.
The antidepressant response to escitalopram was milder and no changes in brain network organization were observed.
The combination of mutation profiling and CNA profiling can improve the detection of MRD, which may help optimize the treatment strategies for patients with LARC.
Roxadustat effects on statin C max and AUC inf were statin and administration time dependent.
The planned sample size, 950 patients, was calculated to permit accumulation of sufficient overall survival events in 5 years to achieve 90% power for the overall survival primary endpoint.
NEW & NOTEWORTHY: This study indicated that exogenous progesterone does not reduce LH pulse frequency within 12 h in women with PCOS, but progesterone acutely increased gonadotropin in these women.
Our current study is the largest thus far study reporting CXCL16 levels in COVID-19 hospitalized patients (with whole-genome sequencing data available).
Liraglutide add-on therapy reduced HbA1c levels without increasing low blood sugar incidence, independent of BMI, in insulin non-responders with type 2 DM.
Based on data derived from the anchor method, reductions in PAC-SYM and PAC-QOL scores of >1.0 in patients with chronic noncancer pain and opioid-induced constipation are clinically meaningful.
These findings provide insight into the R/R AML molecular profile and the impact of FLT3 inhibitors on mutational evolution associated with treatment resistance and benefit of gilteritinib.
The PORT trial aims to generate evidence that additive/adjuvant chemotherapy after definitive treatment of colorectal metastases improves progression free and overall survival in patients with colorectal cancer.
Heart rate was unchanged in both treatment groups.
Alcohol-dependent patients with favorable prognostic factors such as non-smoking status, no family history of problem drinking, and a late-onset of problem drinking selectively benefit from nalmefene.
In mechanically ventilated participants with nosocomial pneumonia owing to Gram-negative pathogens, ceftolozane/tazobactam was comparable with meropenem for per-pathogen 28 day ACM and clinical and microbiological response.
Tanezumab and NSAID both provided early and sustained (up to 56 weeks) efficacy relative to baseline.
Study findings will help develop bio-efficacy and physical durability criteria for partner A.I., in relation to the cRCT epidemiological and entomological outcomes, and refine preferred product characteristics of each class of...
Clinicaltrials.gov registration: NCT03032380.
The study demonstrated a reduction of the telogen rate by a cosmetic foam in men affected by AGA, indicating a benefit for cosmetic intervention against male pattern hair loss.
Cabozantinib improved OS and PFS versus placebo in both ALBI grade 1 (hazard ratio [HR] [95% CI]: 0.63 [0.46-0.86] and 0.42 [0.32-0.56]) and ALBI grade 2 (HR [95% CI]: 0.84 [0.66-1.06] and 0.46 [0.37-0.58]) subgroups.
S1918 has the potential to impact future trial design and to change the standard of care for patients 75 years and older with aggressive lymphoma given its randomized design, prospective incorporation of older adults...
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
